Kailera Therapeutics, Inc.
NASDAQ:KLRA · NASDAQ Global Select
+$0.51 today
Vol 2.59M · Avg 0.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jamie Beth Coleman | Chief Commercial Officer | $911,283.00 | — | 48 | $0.00 | <0.01% |
Ronald C. Renaud Jr. | President, CEO & Director | $863,871.00 | — | 57 | $38,094.00 | 0.03% |
Paul Douglas Burgess | Chief Operating & Business Officer | $670,190.00 | — | 52 | $0.00 | <0.01% |
Corey Manchester | Treasurer | — | — | — | — | — |
Scott Wasserman | Chief Medical Officer | — | — | 56 | $0.00 | <0.01% |
Maura Gavaghan | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Scott Akamine | Chief Legal Officer & Secretary | — | — | 41 | $0.00 | <0.01% |
Paula A. Cloghessy SHRM-SCP SPHR | Chief People Officer | — | — | 54 | $0.00 | <0.01% |
Douglas W. Pagan | Chief Financial Officer | — | — | 54 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$326.75M
Sells
0
$0.00
Net Sentiment
+$326.75M
Net buying
Most Active
Kaplan Andrew T.
1 transactions
Analysis
Insiders reported 5 buys worth $326.75M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $326.75M. Kaplan Andrew T. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Peer companies in the same sector
No competitor data available.
Who manages KLRA?
Kailera Therapeutics, Inc. (KLRA) lists 9 active executives. The top listed executive is Corey Manchester, Treasurer.
Are KLRA insiders buying or selling?
Recent insider activity shows net buying of $343.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.